The safety and efficacy of methylnaltrexone in pediatric oncology patients: A single center experience.

Lauren KorantengAudrey MauguenMiriam ButlerShirley Qiong YanDamani Taylor

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Methylnaltrexone appears safe in the pediatric population and produces bowel movements in more than a third of pediatric patients. It is a feasible and safe option for opioid induced constipation in pediatric patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
palliative care
peritoneal dialysis
high glucose
diabetic rats
oxidative stress
young adults
patient reported outcomes